+185.5%
RKLB vs MRNA
-27.3%
+212.7%
-77.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -10.9% | -2.2% | -8.8% | -10.6% |
| 7D | -26.2% | -12.7% | -13.5% | -24.8% |
| 30D | -15.4% | -20.7% | +5.3% | -12.9% |
| 3M | -37.7% | +46.3% | -84.0% | -41.1% |
| 6M | -66.2% | +305.2% | -371.4% | -76.9% |
| YTD | -34.9% | +561.2% | -596.1% | -62.1% |
| 1Y | +15.0% | +772.1% | -757.0% | -38.1% |
| 3Y | +953.8% | +147.0% | +806.9% | +642.1% |
| All | +185.5% | -27.3% | +212.7% | +147.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling